Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study.

Allogeneic hematopoietic stem cell transplantation (alloHSCT) represents the therapeutic option able to offer the highest rate of a successful cure for most children and young adults (AYA) with very high-risk and relapsed acute leukemia or myelodysplasia1. Although the prognosis has largely improved over the decades2,3, survivors after HSCT during childhood or adolescence still have an increased risk of developing long-term toxicities that can interfere with their general health4 and have a detrimental impact on their quality of life5.

Source: Biology of Blood and Marrow Transplantation - January 2, 2024 Category: Hematology Authors: Francesco Saglio, Daria Pagliara, Marco Zecca, Adriana Balduzzi, Alessandro Cattoni, Arcangelo Prete, Francesco Paolo Tambaro, Maura Faraci, Elisabetta Calore, Franco Locatelli, Franca Fagioli, On Bhealf of AIEOP BMT Group Source Type: research